1. Scrip
  2. >>Business
  3. >>Earnings

Lilly Tries To Keep Investors Focused On The Pipeline, Not Performance

 
• By Joseph Haas

With disappointing revenues during Q1 due to the pandemic impact on sales and price pressure on Taltz, the pharma gave a long-term, pipeline-focused growth narrative. Alzheimer's filing plans pushed back.

Lilly
Lilly has increased R&D spending guidance with focus on long-term growth

Eli Lilly and Company primarily used its first quarter 2021 earnings call on 27 April to point out some of its long-term plays, particularly the Alzheimer’s disease candidate donanemab and type 2 diabetes candidate tirzepatide. And it might take a while to deliver on those potentially game-changing opportunities: the pharma revealed that it will not seek accelerated approval of donanemab based on Phase II data.

A lesser focus of the call was on the quarterly performance; while Lilly’s year-over-year sales revenue increased by 16%, several products fell short of analyst estimates, notably its COVID-19 neutralizing antibody

More from Earnings

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s Most Favored Nation Policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company, as she and MD Nilesh Gupta outline a five-year plan focused on complex generics and technology platforms

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.